

HEALTHCARE INDUSTRY Q3 2024 VALUATION UPDATE

2

2



Table of Content

Industry Overview

Global Comparable Public Companies

Global Transactions

About Seale





Introduction

We are pleased to share our Healthcare Industry Multiples Valuation Update for Q3 2024.

At Seale & Associates, we are committed to providing process-driven solutions designed to optimize value and achieve our client's strategic objectives in a range of transactions, including Mergers, Acquisitions, Divestitures and Carve-Outs, Business Sales, Recapitalizations, and Joint Ventures, among other corporate finance and strategy consulting services.

Over the course of 25+ years, we have successfully served clients all over the world, and we are delighted to continue providing investment banking advisory services to our clients who are looking to grow through acquisitions or optimize their portfolios through strategic divestitures.

Seale has extensive experience advising leading multinational companies, private equity firms, and family-owned businesses across a wide range of industries.



James A. Seale | President jseale@sealeassociates.com



Brett M. Carmel | Senior Managing Director bcarmel@sealeassociates.com



Robert Whitney | Managing Director rwhitney@sealeassociates.com



Sergio Garcia del Bosque | Managing Director sgarcia@sealeassociates.com



Carlos Hernández Goudet | Managing Director chernandez@sealeassociates.com





Alejandro Montemayor | Vice President amontemayor@sealeassociates.com

Armando Rios | Vice President arios@sealeassociates.com



Healthcare's Industry Overview, M&A Trends and Market Intelligence


Healthcare M&A Trends and Market Intelligence

- The demand for innovative solutions, particularly in digital health, personalized medicine, and advanced diagnostics, remained strong, driven by patient-centric care models. Biotechnology and life sciences sectors continued to attract high valuations, with a growing emphasis on gene therapies and precision medicine, bolstering investor confidence
- **M&A activity** in the industry remained **strong**, with **strategic buyers** accounting for 90% of the transaction volume, while **financial buyers** represented the remaining **10%**
- Healthcare EBITDA multiples remained stable at historically elevated levels in Q3 2024, except for the **Biotechnology segment**, which saw rapid growth of 38.0% YTD, following a similar increase in 2023. In comparison, the S&P 500's multiple growth was 26.0% YOY
- **Political landscape introduced uncertainties**, **particularly** with the potential rollback of measures like expanded Medicaid and ACA subsidies, which had previously benefited hospitals. The appointment of figures with critical views on healthcare spending signaled **possible reductions in funding and increased** oversight for hospitals
- The sector saw a continued **focus on digital health** innovations, including telehealth services and Al-driven diagnostics. These advancements aimed to enhance patient care and operational efficiency, addressing some of the challenges posed by labor shortages and increasing demand for personalized medicine
- Healthcare services and technology companies face sharp valuation declines, with some shutting down despite cutting R&D and acquisition costs. This creates opportunities for strategic and PE investors to acquire talent and capabilities at favorable terms. Not-for-profit health systems, supported by past refinancing, can also diversify through timely acquisitions
- In summary, Q3 2024 was marked by a blend of growth opportunities and challenges within the healthcare industry. While financial performance and M&A activity indicated resilience, regulatory uncertainties and operational hurdles require strategic adaptations to maintain momentum

Source: Capital IQ, Wall Street Journal, McKinsey and Other Industry Reports

Healthcare Industry M&A Deal Size and Volume








Pharmaceutical Producers Global Comparable Public Companies (1/3)

		Market	Enterprise	Revenue	EBITDA		Average BITDA	Third Qua Sep. 30, 2	
Company	Count	ry Cap. US\$M	Value US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Rev
AbbVie Inc.	abbvie USA	\$348,818	\$406,642	\$55,533	47.6%	11.2x	10.5x	15.4x	7
Astellas Pharma Inc.	Tastellas JPN	\$20,614	\$25,428	\$12,370	15.7%	11.0x	10.3x	13.1x	2
AstraZeneca PLC	AstraZeneca 😒 GBR	\$240,782	\$269,050	\$51,206	33.6%	21.7x	14.7x	15.6x	5.
Bausch Health Companies Inc.	BAUSCH CAN	\$2,996	\$25,009	\$9,474	32.5%	8.3x	8.4x	8.1x	2.
Bristol-Myers Squibb Company	راله Bristol Myers Squibb USA	\$104,897	\$151,971	\$47,435	41.2%	8.9x	8.3x	7.8x	3.
Catalent, Inc.	Catalent. USA	\$10,991	\$15,690	\$4,422	12.4%	16.6x	17.0x	28.7x	3.
Daiichi Sankyo Company, Limited	🔘 Daiichi-Sankyo JPN	\$62,476	\$57,564	\$12,271	18.4%	46.8x	48.6x	25.5x	4
Eisai Co., Ltd.	Eisai JPN	\$10,550	\$9,868	\$5,257	9.5%	37.5x	49.5x	19.8x	٦.
GSK plc	gsk gbr	\$82,908	\$100,811	\$41,966	35.7%	8.8x	7.3x	6.7x	2.
Johnson & Johnson	Johnson-Johnson USA	\$390,118	\$406,134	\$87,696	35.6%	14.0x	12.6x	13.0x	4





Pharmaceutical Producers Global Comparable Public Companies (2/3)

Company	Country	Market y Cap.	Enterprise Value	Revenue US\$M	Revenue EBITDA		Average BITDA	Third Quarte Sep. 30, 2024	
Company	Country	US\$M	US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Revo
Merck & Co., Inc.	MERCK USA	\$287,853	\$314,353	\$63,174	37.9%	11.1x	12.6x	13.1x	5.
Novartis AG	U NOVARTIS CHE	\$232,847	\$254,894	\$49,940	41.0%	6.2x	10.5x	12.4x	5
Novo Nordisk A/S	DNK novo nordisk [®]	\$521,589	\$520,753	\$40,468	47.3%	25.1x	29.3x	27.2x	12
Otsuka Holdings Co., Ltd.	Otsuka JPN	\$30,549	\$29,202	\$15,842	21.3%	9.4x	7.9x	8.6x	1.
Pfizer Inc.	Pfizer USA	\$163,994	\$227,027	\$59,375	19.3%	7.6x	6.3x	19.8x	3.
Roche Holding AG	Roche CHE	\$257,624	\$294,672	\$71,718	35.2%	12.1x	9.8x	11.7x	4
Sanofi	sanofi FRA	\$143,853	\$163,106	\$54,032	24.7%	10.5x	9.1x	12.2x	3.
Shionogi & Co., Ltd.	SHIONOGI JPN	\$12,190	\$10,427	\$2,921	36.6%	19.7x	8.5x	9.7x	3.






















Pharmaceutical Producers Global Comparable Public Companies (3/3)

		Market	Value	Revenue	EBITDA				l Quarte 30, 2024	
Company	Country	Cap. US\$M	Value US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Rev	
Sun Pharmaceutical Industries Limited	SUN IND	\$55,196	\$53,718	\$6,007	26.4%	20.6x	21.5x	33.8x	8	
Takeda Pharmaceutical Company Limited	Takeda JPN	\$45,389	\$82,340	\$31,732	27.1%	8.6x	9.4x	9.6x	2	
Teva Pharmaceutical Industries Limited		\$20,417	\$37,285	\$16,772	28.0%	7.0x	7.4x	7.9x	2	
UCB SA	BEL	\$34,279	\$37,190	\$6,083	21.7%	11.2x	14.1x	28.1x	6	
Excluded from mean and median					Mean	10.7x	10.3x	12.0x	3.	
					Median	11.2x	10.4x	13.1x	3	






Medical Devices & Consumables Global Comparable Public Companies (1/2)

Company	Count	Market	Enterprise	Revenue	EBITDA	Annual A EV/EB		Third (Sep. 30	Ŭ
Company	Countr	y Cap. US\$M	Value US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Reve
Ansell Limited	Ansell Aus	\$3,191	\$3,149	\$1,619	16.4%	8.0x	8.8x	11.9x	1.'
Baxter International Inc.	Baxter USA	\$19,371	\$30,684	\$15,062	20.3%	14.8x	10.8x	10.0x	2.
Becton, Dickinson and Company	BD USA	\$69,688	\$83,701	\$19,828	26.5%	16.1x	17.7x	15.9x	4.
Boston Scientific Corporation	Scientific USA	\$123,406	\$131,667	\$15,911	25.4%	20.9x	24.4x	32.5x	8.
Cardinal Health, Inc.	CardinalHealth [™] USA	\$26,742	\$27,113	\$224,454	1.3%	7.8x	9.2x	9.0x	0
ConvaTec Group PLC	GBR	\$6,227	\$7,622	\$2,200	22.6%	15.8x	15.2x	15.3x	3.
Edwards Lifesciences Corporation	E Edwards Lifesciences USA	\$39,752	\$38,523	\$6,315	32.6%	32.9x	25.2x	18.7x	6
Hogy Medical Co.,Ltd.	HOGY. JPN	\$702	\$595	\$273	27.0%	7.3x	6.7x	8.1x	2.
ICU Medical, Inc.	icumedical USA	\$4,451	\$5,805	\$2,340	12.3%	21.5x	18.4x	20.1x	2.
JMS Co.,Ltd.	JPN	\$85	\$198	\$474	5.9%	6.2x	6.8x	7.1x	Ο.

























Medical Devices & Consumables Global Comparable Public Companies (2/2)

Company		Souptry	Market	Enterprise Value	Revenue	EBITDA		Average BITDA	Third Quarte Sep. 30, 2024	
Company		Country	Cap. US\$M	US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Rev
Medtronic plc	Medtronic	IRL	\$115,463	\$135,653	\$32,577	28.5%	23.3x	14.5x	14.6x	4
Merit Medical Systems, Inc.		USA	\$5,753	\$5,987	\$1,326	19.7%	23.0x	18.0x	22.9x	4
Owens & Minor, Inc.	Owens & Minor	USA	\$1,210	\$3,346	\$10,661	7.3%	8.3x	8.5x	4.3x	0
Sewoon Medical Co., Ltd	SEWOON MEDICAL CO.LTD	KOR	\$89	\$31	\$47	30.1%	10.8x	5.6x	2.2x	0.
Stryker Corporation	stryker	USA	\$137,667	\$148,454	\$21,974	25.7%	25.2x	21.2x	26.3x	6.
Teleflex Incorporated	Global Knowledge Network	USA	\$11,653	\$13,243	\$3,026	21.9%	27.4x	17.3x	20.0x	4.
West Pharmaceutical Services, Inc.	West	USA	\$21,774	\$21,642	\$2,876	28.0%	39.2x	25.0x	26.9x	7.
Excluded from mean and median						Mean	12.8x	12.7x	12.3x	2.
						Median	15.8x	15.2x	15.3x	3.







6.8x



7.5x



Drug Stores Global Comparable Public Companies

Company		Country	try Cap. Value		Revenue EBITDA e US\$M Margin		Average BITDA	Third Quarte Sep. 30, 202		
Company		soundry	US\$M	US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Rev
Corporativo Fragua, S.A.B. de C.V.	FRAGUA	MEX	\$4,414	\$4,229	\$6,012	5.6%	6.8x	7.8x	12.5x	0
CVS Health Corporation	CVS Health	USA	\$79,102	\$146,843	\$367,246	5.2%	8.8x	7.0x	7.6x	0.
Dimed S.A. Distribuidora de Medicamentos	DIMED	BRA	\$277	\$432	\$885	5.6%	11.6x	10.0x	8.7x	0
Empreendimentos Pague Menos S.A.	Pague Menos	BRA	\$279	\$912	\$2,233	6.6%	7.9x	7.5x	6.2x	0.
Farmacias Benavides, S.A.B. de C.V.	benavides.	MEX	\$418	\$593	\$904	10.6%	4.4x	4.8x	6.2x	0
Raia Drogasil S.A.	RaiaDrogasil S.A.	BRA	\$8,029	\$9,356	\$6,924	10.1%	15.3x	15.4x	13.3x	٦.
Walgreens Boots Alliance, Inc.	Walgreens Boots Alliance	USA	\$7,735	\$42,476	\$147,658	5.1%	7.9x	9.5x	5.6x	0
Excluded from mean and median						Mean	8.6x	8.4x	7.2x	0.
						Median	7.9x	7.8x	7.6x	0.





















Pharmaceutical Products – Q3 Global Transactions (1/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Sep-24	Worldwide Rights of DESFERAL®	CHE	Mitem Pharma , provider of medicines MITM, acquired worldwide rights of DESFERAL , injectable medicine for the treatment of iron overload, from Novartis, complementing its portfolio of MITMs	mitem pharma	U NOVARTIS	100.0%	-	-	
Sep-24 [*]	RLS (USA)	USA	Telix , provider of radiopharmaceuticals, agreed to acquire RLS (USA) , radiopharmacy network, expanding its manufacturing footprint and establishing a next-generation radiometal network	() Telix	RADIOPHARMACIES	100.0%	\$250.0	-	
Sep-24	& dermavant™	GBR	Organon , provider of women's healthcare products, acquired Dermavant , developer of dermatologic therapies, expanding its dermatology portfolio with VTAMA® (tapinarof) cream	- CRGANON	-	100.0%	\$1,486.0	-	
Sep-24 [*]	VECTURA	GBR	Molex Asia Holdings, provider of electronics and connectivity solutions, agreed to acquire Vectura , provider of pharmaceutical therapies, from Vectura Fertin Pharma, enhancing its product portfolio	molex	Vectura Fertin Pharma	100.0%	\$392.4	-	
Sep-24	Seaview Enterprises	USA	Hims & Hers, telehealth company, acquired Seaview Enterprises, provider of generic prescription medicines, from Nivagen, enhancing its manufacturing capabilities	hims & hers	NIVAGEN	100.0%	\$28.8	-	
Aug-24	PHARMACEUTICALS	USA	KE Manufacturing , provider of human capital management solutions, merged with Titan , manufacturer of biopharmaceutical products, enhancing Titan's strategic direction by integrating KE's expertise in human capital management	K.E.Manufacturing Sdn. Bhd.	-	Merger	\$21.6	-	







Pharmaceutical Products – Q3 Global Transactions (2/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Aug-24	REVANCE THERAPEUTICS	USA	Crown , manufacturer of skincare products, merged with Revance Therapeutics , manufacturer of neuromodulator offerings, aiming to become a fully integrated global aesthetics and skincare company	C R O W N'	-	Merger	\$1,212.4	-	
Aug-24 [*]	Therakos [®] ECP Immunomodulation	FRA	CVC , private equity firm, agreed to acquire Therakos , provider of extracorporeal photopheresis (ECP) systems, from Mallinckrodt, expanding its healthcare portfolio	CVC CAPITAL PARTNERS	Mallinckrodt	100.0%	\$925.0	-	
Jul-24	IRONSHORE PHARMACEUTICALS	CAN	Collegium , specialty pharmaceutical company focused on pain management, acquired Ironshore , provider of ADHD treatments, expanding its portfolio into neurology and establishing a presence in the ADHD market	Collegium.	-	100.0%	\$525.0	-	
Jul-24 [*]	HEPION PHARMACEUTICALS	USA	Pharma Two B , provider of Parkinson's disease products, agreed to merge with Hepion , provider of biopharmaceutical products, facilitating Pharma Two B's public market entry and advancing P2B001's development	Pharma Two B	-	Merger	\$58.5	-	
Jul-24	VALINOR	USA	Grünentha l, provider of pain management solutions, acquired Valinor , provider of Movantik® (naloxegol), strengthening its U.S. presence and becoming the global owner of Movantik®	GRÜNENTHAL	-	100.0%	\$250.0	-	
Jul-24	Womens Health Specialty Business	USA	Evofem Biosciences , provider of biopharmaceutical products for women's health, acquired Women's Health Specialty Business from Lupin , expanding its portfolio and strengthening its position in women's health	E OFEM BIOSCIENCES [®]	HARMACEUTICALS, INC.	100.0%	\$84.0	-	
*Announce	ed transactions pendina	approval an	d other closing conditions				Mean	_	

*Announced transactions pending approval and other closing conditions

- Mean
- Median -







1.6x

Medical Equipment - Q3 Global Transactions (1/3)

Date	Target	Country	Description
Sep-24	⊘ spire health	USA	Wellinks Inc , provider of digital healthcare solutions, acquired Spi health-tracking devices and remote patient monitoring solutions, creating a fully integrated "predictive patient care" company
Sep-24	oventure	ESP	Austell , pharmaceutical company, acquired Noventure , provider of devices, from Grupo Ferrer, enhancing its portfolio in gastroentero pediatrics, and dermatology
Sep-24	MORGAN	USA	Vitalograph , provider of respiratory diagnostic solutions, acquired customer-facing software for advanced pulmonary function testin strengthening its commercial footprint
Sep-24	gri. THINK. MAKE. PROTECT.	USA	Winner , manufacturer of wound care and surgical Products acqui Resources International , manufacturer of healthcare equipment, internationally
Sep-24	ovizio	BEL	ChemoMetec , manufacturer of instruments for cell counting, acquimanufacturer of digital holographic interferometric microscopy product portfolio
Sep-24 [*]		DEU	German-American consortium agreed to acquire Apoplex Medic manufacturer of medico-technical instruments and supplies, from realigning its operations
Sep-24 [*]	BIOLASE LEADER IN DENTAL LASERS [®]	USA	Sonendo , provider of the GentleWave® System, agreed to acquire of dental laser systems, enhancing its technology platform

	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
pire Health , provider of s, from Gilde Healthcare,		HEALTHCARE PARTNERS	100.0%	-	-	
r of licensing medical rology, urogynecology,	Medicine with a conscience	🚺 ferrer	100.0%	-	-	
ed Morgan , provider of ing (PFT) systems,	Malograph	-	100.0%	-	-	
uired a stake in Global t, expanding	winner	-	75.2%	\$120.0	7.8x	
quired Ovizio , products, increasing its	chemometec	-	100.0%	\$3.2	-	
ical Technologies , m Geratherm,	German-American consortium	Geratherm®	60.6%	\$18.3	-	
re Biolase , manufacturer	Saving teeth. Restoring health.	-	100.0%	\$14.0	-	











Medical Equipment - Q3 Global Transactions (2/3)

Date	Target	Country	Description
Sep-24	MEDICA NUTRINIEN CONCENSION	USA	Nihon Kohden , manufacturer of medical devices, acquired a stake of specialized electrodes for neurodiagnostic procedures, from Arc neurology portfolio
Sep-24	Osteotomy Truss System and Ankle Truss System	USA	Stryker , provider of medical technologies, acquired the Osteotom Ankle Truss System , providers of healthcare products, reflecting is providing surgeons with enhanced orthopedic solutions
Sep-24	Quality products for life	USA	Veridian Healthcare , provider of diagnostic products, acquired Ze telehealth and remote patient monitoring devices, positioning as diagnostic medical and telehealth products in North America
Aug-24	Vertos	USA	Stryker , provider of medical technologies, acquired Vertos Medica devices, primarily minimally invasive treatments for lumbar spinal its interventional pain management portfolio
Aug-24	PARAGONIX	USA	Getinge , provider of medical technology, acquired Paragonix , pro- transport products, enhancing its portfolio in organ preservation a
Aug-24 [*]	Vantive	NLD	The Carlyle Group and Atmas Health, investment firms, agreed to Health, provider of kidney care equipment, from Baxter, aiming to into a standalone global business
Aug-24	simple, bright ideas.	USA	Cooper Surgical , provider of women's health and fertility solutions Surgical , provider of surgical retractors with integrated multi-LED evacuation channels, providing clinicians with a broader range of s

	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
ke in Ad-Tech , provider Archimed, enhancing its	NIHON KOHDEN	ARCHIMED	71.4%	-	-	
my Truss System and g its commitment to	stryker	4VEB MEDICAL	100.0%	-	-	
Zewa , provider of as a leading supplier in		-	100.0%	-	-	
ical , provider of medical al stenosis, enhancing	stryker	_	100.0%	-	-	
rovider of organ n and transportation	getinge 🛠	SIGNET Healthcare Partners	100.0%	\$477.0	-	
to acquire Vantive to transform Vantive		Baxter	100.0%	\$3,800.0	-	
ns, acquired Obp D light and dual smoke of surgical technologies	CooperSurgical®	-	100.0%	\$100.0	-	









Medical Equipment - Q3 Global Transactions (3/3)

Date	Target	Country	Description
Jul-24	precision surgery made simpler®	CAN	Stryker , provider of medical technologies, acquired MOLLI , manuf soft tissue localization systems, enhancing its solutions portfolio in
Jul-24	JENAVALVE	USA	Edwards Lifesciences , provider of heart disease and critical care n agreed to acquire JenaValve , manufacturer of transapical transcar implantation systems, expanding its portfolio offering
Jul-24 [*]	ENDOTRONIX	USA	Edwards Lifesciences , provider of heart disease and critical care nagreed to acquire Endotronix , manufacturer of implantable pressents structural heart portfolio
Jul-24 [*]	ROTECH [®] HEALTHCARE INC.	USA	Owens & Minor , provider of healthcare solutions, agreed to acquir manufacturer of home medical equipment, enhancing its patient
Jul-24 [*]		USA	Astorg , private equity firm, agreed to acquire Hamilton Thorne , m precision instruments, laboratory equipment, consumables, softw creating a comprehensive provider of high-quality equipment
Jul-24	Sleep Testing Diagnostic Technology	USA	EnsoData , provider of healthcare technology, acquired sleep testi technology from Resonea , provider of sleep diagnostic devices, er data-driven approach to pre-screening patients
Jul-24	AJR ENTERPRISES	USA	UFP Technologies , manufacturer of solutions for medical devices, Enterprises , manufacturer of single-use safe patient handling syst patient surfaces portfolio

*Announced transactions pending approval and other closing conditions

	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	R
ufacturer of wire-free in breast cancer care	stryker	-	100.0%	-	-	
e monitoring equipment, catheter aortic valve	E Edwards Lifesciences	-	100.0%	\$945.0	-	
e monitoring equipment, ssure sensors, expanding	É Edwards Lifesciences	-	100.0%	\$675.0	-	
uire Rotech Healthcare , nt direct segment	Owens & Minor*	-	100.0%	\$1,320.0	6.3x	
manufacturer of ware, and services,	ostorg.	-	100.0%	\$282.0	-	
sting diagnostic enabling a mobile-first,	Šensodata	RESONEA	100.0%	-	-	
es, acquired AJR vstems, enhancing its	UFP TECHNOLOGIES	-	100.0%	\$120.8	6.6x	
				Mean	6.9x	
				Median	6.6x	











1.6x

1.2x 1.3x

Hospitals – Q3 Global Transactions (1/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	l Rev
Sep-24	Fort Myers Healthcare Facilities	USA	Sila Realty Trust , real estate investment trust, sold the Fort Myers Healthcare Facilities , two vacant properties formerly leased to GenesisCare, aiming to streamline its portfolio and reallocate capital	-	realty trust	100.0%	\$15.5	-	
Sep-24	29-Property Skilled Nursing Portfolio in Iowa	USA	Cascade Capital Group , private equity firm, acquired 29 long-term care properties in Iowa , from ABCM, expanding its presence in the healthcare real estate sector	CASCADE CAPITAL GROUP	ABCM Corporation www.abcmcorp.com	100.0%	\$85.0	-	
Aug-24	Good Samaritan and St. Elizabeth's Medical Center	USA	Boston Medical Center, academic healthcare system, acquired Good Samaritan Medical Center and St. Elizabeth's Medical Center, from Steward Health Care System, increasing capabilities	EXCEPTIONAL CARE. WITHOUT EXCEPTION.	© Steward Steward Health Care System	100.0%	-	-	
Aug-24 [*]	REGIONAL MEDICAL CENTER	USA	County of Santa Clara , provider of healthcare services, agreed to acquire Santa Regional Medical Center (RMC) , acute-care hospital, reinforcing healthcare access in East San Jose	County of Santa Clara	HCA* Healthcare®	100.0%	\$175.0	-	
Aug-24	Morton and Steward St. Anne's Hospitals	USA	Lifespan Corporation , provider of healthcare services in Rhode Island, acquired St. Anne's Hospital and Morton Hospital , from Steward Health Care, enhancing its Massachusetts healthcare footprint and service offerings	Lifespan Delivering health with care*	© Steward Steward Health Care System	100.0%	\$175.0	-	
Aug-24	11 Healthcare Facilities in Colorado	USA	UCHealth , nonprofit health system in Colorado, acquired 11 healthcare facilities , from Medical Properties Trust, enhancing its statewide outpatient services portfolio	uchealth	Medical Properties Trust	100.0%	\$86.0	-	







Hospitals - Q3 Global Transactions (2/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Aug-24 [*]	revere medical	USA	Rural Healthcare Group (RHG) , provider of healthcare services, agreed to acquire Stewardship , provider of physician-led multispecialty services now known as Revere Medical, expanding its national footprint	rural healthcare group	© Steward Steward System	100.0%	-	-	
Aug-24	Medical facility in Florida	USA	Global Medical REIT , real estate investment trust, sold a medical facility in Panama City, Florida, resulting in a \$1.7 million gain, as part of its capital recycling plan	_	GLOBAL MEDICAL REIT	100.0%	\$49.5	-	
Aug-24	Brookwood Baptist Health.	USA	Orlando Health , provider of healthcare services, acquired a 70% stake in Brookwood Baptist Health , network of hospitals, from Tenet Healthcare, adding five Birmingham- area hospitals and expanding into Alabama	ORLANDO HEALTH °	Tenet Health	70.0%	\$910.0	-	
Aug-24	53 Nursing facilities	CAN	Pacs Group, investment compnay, acquired 53 skilled nursing, assisted, and independent living facilities, from Prestige Care, extending its footprint	PACS	-	100.0%	\$43.0	-	
Jul-24	Fort Smith Inpatient Rehabilitation Facility	USA	Sila Realty Trust , real estate investment trust, acquired a 50-bed rehabilitation facility in Fort Smith, Arkansas, enhancing its healthcare portfolio	realty trust	-	100.0%	\$28.3	-	
Jul-24	8 Arizona Facilities	USA	Dignity Health , provider of health care services, acquired 8 Arizona facilities , from Medical Properties Trust, expanding capabilities	Straight Straight Bealth	Medical Properties Trust	100.0%	\$160.0	-	

*Announced transactions pending approval and other closing conditions







Drug Stores – Q3 Global Transactions

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Sep-24	Pharmacy business	CAN	PharmaCorp , pharmacy chain, acquired pharmacy business including land and buildings in Canada, boosting growth	PharmaCorp 🔗	-	100.0%	#VALUE!	-	
Sep-24	Farmacia desde 1910	URY	Farmashop , pharmacy chain, acquired Farmacia Pasteur , century-old phamacy chain operating five stores, expanding its presence beyond Montevideo	farmashop Lecuida	-	100.0%	-	-	
Sep-24	C&R Pharmacy	USA	Waverley Pharma , provider of therapeutics, acquired C&R Pharmacy , an independent pharmacy in Ohio, generating immediate revenue and supporting local community healthcare	Waverley Pharma	-	100.0%	\$0.5	-	
Sep-24 [*]	Rexall	CAN	Birch Hill , private equity firm, agreed to acquire Rexall Pharmacy Group , pharmacy chain with 385 locations, strengthening its presence in the Canadian healthcare market	BIRCH HILL equity partners	MCKESSON Canada	100.0%	-	-	
Aug-24	Desde 1891 La Danesa FARMACIAS	ARG	FarmaPlus , pharmacy chain operating in Buenos Aires and its suburbs, acquired Farmacia La Danesa , retailer pharmacy with four locations in the Belgrano neighborhood, strengthening its presence in the city	FarmaPlus	-	100.0%	\$4.5	-	
Aug-24	VFP PHARMACY GROUP	USA	BelHealth Investment Partners , private equity firm, divested VFP Pharmacy Group , national fertility pharmacy, after growing its revenues fivefold through organic growth and strategic acquisitions	-	BELHEALTH Investment Partners	100.0%	-	-	
Jul-24	HomeFree PHARMACY SERVICES	USA	AnewHealth , pharmacy care management provider, acquired HomeFree Pharmacy, provider of pharmacy services, strengthening dedication to delivering a comprehensive level of medication-related care	/ anew health	-	100.0%	-	-	
Jul-24	KEYSTONE SPECIALTY PHARMACY A NEW APPROACH	USA	Novastone Capital Advisors, private equity firm, acquired Keystone Specialty Pharmacy, specialty pharmacy, enhancing its healthcare portfolio	NOVASTONE CAPITAL ADVISORS	-	100.0%	-	-	
*Announce	ed transactions pending o	approval an	d other closing conditions				Mean Median	-	









TARGET Sensi-Care and Aloe Vesta

TRANSACTION TYPE Sell-side Advisory

INDUSTRIES

Healthcare, Personal Care

GEOGRAPHY Reading, GBR

SITUATION

Seale & Associates acted as financial advisor to ConvaTec Group (LON: CTEC) on the divesture of Sensi-Care and Aloe Vesta to Medline Industries. ConvaTec Group (LON: CTEC), is a global medical products company based in the United Kingdom.

SEALE & ASSOCIATES' APPROACH

Seale managed a competitive auction process with potential strategic and financial buyers for Sensi-Care and Aloe Vesta. Seale's disciplined approach allowed our client to maintain momentum, negotiating leverage throughout the process and ensure closing at a premium value and more favorable terms.

OUTCOME

The process resulted in a successful acquisition of Sensi-Care and Aloe Vesta by Medline Industries, a healthcare company with almost USD\$14 billion in annual sales. The divestiture is part of ConvaTec's strategy to focus on its core businesses and markets.

HEALTHCARE Q3 2024



"Seale was instrumental in keeping the process moving in a swift, orderly fashion"



"Seale was instrumental in keeping the process moving in a swift, orderly fashion. Their common sense and ability to find simple, common ground solutions while preserving our interests were invaluable in bringing this project to a successful conclusion."

George Landau, Vice President of Corporate **Development** at ConvaTec

TARGET Laboratorios Portugal S.R.L

TRANSACTION TYPE Acquisition Advisory

INDUSTRIES

Healthcare, Pharmaceutical

GEOGRAPHY Peru

SITUATION

Seale & Associates acted as exclusive financial advisor to Invekra, assisting with comprehensive research on the Peruvian pharmaceutical market and the prioritization of potential acquisition targets.

SEALE & ASSOCIATES' APPROACH

Seale completed a thorough screening of the potential universe of pharmaceutical companies that would align with Invekra's strategy. Seale pre-qualified each potential target and initiated transaction discussions with the targets that best fit Invekra's strategy and investment criteria.

OUTCOME

The process resulted in a successful acquisition of Laboratorios Portugal S.R.L by Invekra, a conglomerate of 12 Latin American pharmaceutical companies. The acquisition strengthens Invekra's presence in Latin America.

HEALTHCARE Q3 2024

"This acquisition strengthens Invekra's presence in one of the fastest growing markets in Latin America"



"This acquisition strengthens Invekra's presence in one of the fastest growing markets in Latin America."

Carlos Hernández Goudet, Managing Director at Seale & Associates

Sign up for M&A insights

We deliver sector-specific intelligence designed specifically for industry leaders, private equity firms, and their advisors. Our industry reports and featured articles deliver real-time access to key industry data, including:



Emerging industry trends

Quarterly reports covering 30+ industries Monthly reports for the U.S., Mexico, and Colombia

Transaction analysis and market trends

Valuable insights for industry leaders

Receive email updates with our proprietary data, reports, and insights as they are published for the industries that matter to you the most

SUBSCRIBE








Global M&A Representative Engagements









JAMES A. SEALE

President and Founder | Washington, DC



32+ years of global M&A experience, Attorney, CPA Arthur Andersen, and Professor of Global Investment Banking at George Washington University University of Virginia - JD University of Kentucky - BS in Accounting



SERGIO GARCIA DEL BOSQUE

Managing Director | Mexico City, Mexico



+52 (55) 8000-7463

16+ years of global M&A experience IPADE - MBA Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering



CARLOS HERNANDEZ GOUDET

Managing Director | San Luis Potosi, Mexico



14+ years of global M&A experience Columbia University - MBA Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering







Please contact us if you would like further information about M&A trends and/or specific transaction multiples for your industry. © Seale & Associates



BRETT M. CARMEL

Senior Managing Director and Co-founder | Miami, FL

+1 (703) 294-6530

25+ years of global M&A experience and Professor of M&A at Johns Hopkins University

The George Washington University - MBA International Business and MA - International Affairs

University of Florida - BA in Political Science with High Honors



ROBERT E. WHITNEY

Managing Director | Washington, DC

+1 (703) 801-8939

19+ years of global M&A experience, CPA Deloitte & Touche, Corporate Audit and Assurance Services University of Richmond - BS Business Administration in Accounting



FELIPE BUENO

Senior Director | Monterrey, Mexico



+52 (84) 4432-4444

32+ years with Grupo Industrial Saltillo with experience as Director, Corp. Dev. and extensive global commercial experience Instituto Tecnologico y de Estudios Superiores de Monterrey MBA and BS in Industrial Engineering

Monterrey





Creative Solutions. Trusted Advice.

For over 25 years, Seale & Associates has served leading public and private companies from around the world and operating in a broad range of industries with a high level of quality, integrity and independence while presenting innovative ideas and trusted solutions to address their most complex dealings.



YEARS OF **EXPERIENCE** \$50B+

TRANSACTIONS GLOBALLY

Trusted Advisor to Leading Companies Worldwide

We have worked repeatedly with many of the most well-



SERVICES AND SOLUTIONS

Mergers & Acquisitions	Due Diligence / Support
Divestitures	Expert Witness Testimony
Joint Ventures / Alliances	Corporate Finance Adviso
Recapitalizations	Strategy Consulting





Seale & Associates Creative Solutions. Trusted Advice.

